Work

Supplementary Tables and Figures from Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Table S1. Reason for treatment discontinuation Supplementary Table S2. Select laboratory abnormalities by maximum CTCAE grade Supplementary Table S3. Pharmacokinetic parameters for single-agent utomilumab (cycle 1) Supplementary Figure S1. Patient disposition. Supplementary Figure S2. Dose normalized Cmax of single-agent utomilumab in ADA-negative and ADA-positive patients (cycle 2, day 1). Supplementary Figure S3. Lymphocyte subpopulations assessed by flow cytometry over an 8-week (2-cycle) period following treatment with utomilumab.

DOI: 10.1158/1078-0432.22465484

Authors: Neil H. Segal, Aiwu R. He, Toshihiko Doi, Ronald Levy, Shailender Bhatia, Michael J. Pishvaian, Rossano Cesari, Ying Chen, Craig B. Davis, Bo Huang, Aron D. Thall, Ajay K. Gopal

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361886407

Cites:

Cited by:

Related to: 10